Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

Sarep­ta’s lead gene ther­a­py $SRPT may be on clin­i­cal hold, but the brash Duchenne mus­cu­lar dy­s­tro­phy com­pa­ny is con­tin­u­ing its deep dive in­to the field, hand­ing over $30 mil­lion in an eq­ui­ty in­vest­ment in Lac­er­ta in ex­change for a group of CNS ther­a­pies, in­clud­ing one pro­gram fo­cused on Pompe dis­ease.

The biotech re­port­ed the deal just af­ter mar­ket close on Wednes­day, along with a Q2 state­ment show­ing grow­ing sales vol­ume for Ex­ondys 51.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.